1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Cabergoline Tablets

| Trade Name: | DOSTINEX; CABASER |
| Chemical Family: | Mixture |
| Intended Use: | Pharmaceutical product used for lactation inhibition |

2. HAZARDS IDENTIFICATION

Appearance: White tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

| Short Term: |
| Active ingredient may be harmful if swallowed. (based on animal data). Accidental ingestion may cause effects similar to those seen in clinical use. |

Known Clinical Effects:

Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. This drug may decrease the quantity/quality of breast milk.

EU Indication of danger: Not classified


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
### 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabergoline</td>
<td>81409-90-7</td>
<td>Not Listed</td>
<td>Xn;R22</td>
<td>1.25</td>
</tr>
<tr>
<td>Leucine</td>
<td>61-90-5</td>
<td>200-522-0</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose NF, anhydrous</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Symptoms and Effects of Exposure:**
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:**
Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:**
Formation of toxic gases is possible during heating or fire.

**Fire Fighting Procedures:**
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:**
Not applicable

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:**
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:**
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:**
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. It is recommended that all operations be fully enclosed and no air recirculated. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Leucine
Latvia OEL - TWA 5 mg/m³

Cabergoline
Pfizer Occupational Exposure Band (OEB): OEB 5 (control exposure to <1ug/m³)

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets
Molecular Formula: Mixture
Color: White
Molecular Weight: Mixture
10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient(s).

Acute Toxicity: (Species, Route, End Point, Dose)

Cabergoline
- Rat Oral LD 50 383 (F) mg/kg
- Rat Para-periosteal LD 50 22 mg/kg
- Mouse Oral LD 50 202 (F) mg/kg
- Mouse Intravenous LD 50 24 (F) mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Cabergoline
- Skin Sensitization - GPMT Guinea Pig No effect

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Cabergoline
- Embryo / Fetal Development Rat Oral 0.012 mg/kg/day LOAEL Fetotoxicity
- Embryo / Fetal Development Rabbit Oral 8 mg/kg/day NOAEL Not Teratogenic
- Embryo / Fetal Development Mouse Oral 8 mg/kg/day Not Teratogenic, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cabergoline
- In Vitro Mammalian Cell Mutagenicity Hamster Negative
- In Vitro Chromosome Aberration Human Lymphocytes Negative
- In Vitro Micronucleus Mouse Bone Marrow Negative
- In Vitro Direct DNA Damage Bacteria Negative
- Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cabergoline
- 24 Month(s) Rat Oral 0.320 mg/kg/day Not carcinogenic
- 21 Month(s) Mouse Oral 0.980 mg/kg/day Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Cabergoline
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4

Leucine
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 200-522-0

Lactose NF, anhydrous
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>200-559-2</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet